Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Site News
Market: Market:

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises Zacks - Thu May 5, 10:45AM CDT

Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.

AZN : 67.40 (+1.05%)
NVS : 91.46 (+0.22%)
BIIB : 206.20 (+0.97%)
IONS : 37.63 (+2.67%)
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates Zacks - Wed May 4, 7:15AM CDT

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.35% and 9.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

IONS : 37.63 (+2.67%)
NKTR : 3.54 (+2.31%)
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? Zacks - Wed Apr 27, 2:03PM CDT

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IONS : 37.63 (+2.67%)
Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development Zacks - Tue Mar 29, 12:03PM CDT

Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.

BIIB : 206.20 (+0.97%)
COLL : 15.94 (+2.57%)
IONS : 37.63 (+2.67%)
APLS : 42.61 (+1.57%)
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis Globe Newswire - Mon Mar 28, 6:30AM CDT

BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical...

BIIB : 206.20 (+0.97%)
IONS : 37.63 (+2.67%)
Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up Zacks - Fri Feb 25, 9:36AM CST

Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.

AZN : 67.40 (+1.05%)
BIIB : 206.20 (+0.97%)
PFE : 53.91 (-0.15%)
IONS : 37.63 (+2.67%)
Company News for Feb 25, 2022 Zacks - Fri Feb 25, 8:46AM CST

Companies in The News Are: AEP,ATHM,IONS,DISH

AEP : 103.57 (+0.97%)
DISH : 22.30 (+1.36%)
ATHM : 34.01 (+2.81%)
IONS : 37.63 (+2.67%)
Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Beat Estimates Zacks - Thu Feb 24, 7:15AM CST

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 76.25% and 30.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?...

IONS : 37.63 (+2.67%)
INFI : 0.7500 (+24.36%)
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks - Thu Feb 17, 2:02PM CST

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IONS : 37.63 (+2.67%)
2 Unstoppable Growth-Oriented ETFs To Hold for the Long Haul Motley Fool - Thu Feb 17, 9:30AM CST

These funds can take some of the risks out of these exciting but sometimes dangerous sectors.

SBIO : 26.39 (+1.79%)
BLOK : 22.71 (+2.57%)
IONS : 37.63 (+2.67%)

Barchart Exclusives

Gold Moves Back Above The $1800 Level Barchart - Sat May 28, 9:47AM CDT
Gold reached a new record high in early May as Russia invaded Ukraine. Since then, the price corrected, probing below the $1800 level on May 13th and May 16th. The gold futures market stopped correcting at the correct technical level and is now consolidating above the level that was the pivot point throughout most of 2021. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' : 'America/Chicago' ]] CDT
Reserve Your Spot